We are live on ! Find out more
BCTXW

BriaCell Therapeutics Corp Warrant
BCTXW

Delisted

BCTXW was delisted on the 26th of February, 2026.

Back to rankings

7 hedge funds and large institutions have $4.26M invested in BriaCell Therapeutics Corp Warrant in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

17% more capital invested

Capital invested by funds: $3.64M → $4.26M (+$616K)

0.7% more ownership

Funds ownership: 9.04% → 9.73% (+0.7%)

0% more funds holding

Funds holding: 7 → 7 (0)

81% less call options, than puts

Call options by funds: $619K | Put options by funds: $3.33M

Holders
7
Holders Change
–
Holders Change %
0%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
1
Closed
–
Calls
$619K
Puts
$3.33M
Net Calls
-$2.71M
Net Calls Change
-$509K

Top Buyers

Rank Fund Capital Flow
1
PFM
Privium Fund Management
Netherlands
+$236K
2
KJHP
K.J. Harrison & Partners
Ontario, Canada
+$93.9K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$6.39K

BCTXW Hedge Fund Activity: Q3 2022 in Review

7 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in BriaCell Therapeutics Corp Warrant (BCTXW) for Q3 2022, worth a combined $4.26M — up 17% from $3.64M a quarter earlier.

Fund positioning in BCTXW was balanced in Q3 2022: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 1 trimmed.

The largest buyer was Privium Fund Management, adding an estimated $236K. The largest seller was UBS Group, cutting an estimated $6.39K.

  • 7 institutional investors held BriaCell Therapeutics Corp Warrant (BCTXW) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $4.26M of BriaCell Therapeutics Corp Warrant stock for Q3 2022, up 17% quarter-over-quarter.
  • 0 funds opened new BriaCell Therapeutics Corp Warrant positions in Q3 2022 and 0 closed out.
  • The largest BriaCell Therapeutics Corp Warrant buyer in Q3 2022 was Privium Fund Management, an estimated $236K added.
  • The largest BriaCell Therapeutics Corp Warrant seller in Q3 2022 was UBS Group, an estimated $6.39K sold.

Based on aggregated 13F filings for Q3 2022.